share_log

71% Of This Zimmer Biomet Holdings Insider's Holdings Were Sold

71% Of This Zimmer Biomet Holdings Insider's Holdings Were Sold

這位齊默巴奧米特控股內線出售了71%的股份
Simply Wall St ·  01/07 22:36

From what we can see, insiders were net sellers in Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.

從我們所看到的,齊默巴奧米特控股公司(紐交所:ZBH)在過去12個月內,內部人士是淨賣出者。也就是說,內部人士賣出的股票數量大於購買的數量。

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

儘管在長期投資中內部交易並不是最重要的事情,但從邏輯上講,您應該關注內部人員是否買入或出售股票。

Zimmer Biomet Holdings Insider Transactions Over The Last Year

齊默巴奧米特控股公司過去一年內的內部交易

The President of Asia Pacific, Sang Yi, made the biggest insider sale in the last 12 months. That single transaction was for US$1.5m worth of shares at a price of US$115 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$104. So it may not tell us anything about how insiders feel about the current share price. Sang Yi was the only individual insider to sell over the last year.

亞太區總裁楊熙在過去12個月內進行了最大金額的內部出售。單筆交易價值150萬美元,成交價爲每股115美元。我們通常不喜歡看到內部人士的出售,但出售價格越低,我們就越擔憂。好消息是,這筆大額出售價格遠高於當前的104美元。因此,這可能無法告訴我們內部人士對當前股價的看法。楊熙是過去一年內唯一一個出售股票的內部人士。

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

下面的圖表顯示了過去一年內的內部交易(按公司和個人)。通過點擊下面的圖表,您可以查看每筆內部交易的詳細信息!

big
NYSE:ZBH Insider Trading Volume January 7th 2025
紐交所:齊默巴奧米特控股內部交易成交量 2025年1月7日

I will like Zimmer Biomet Holdings better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大型內部買入,我會更喜歡齊默巴奧米特控股。在我們等待的同時,查看這份包含近期內部買入且被低估的小盤股票的免費名單。

Insider Ownership Of Zimmer Biomet Holdings

齊默巴奧米特控股的內部持股

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.1% of Zimmer Biomet Holdings shares, worth about US$28m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

我喜歡查看公司內部人士擁有多少股份,以幫助我了解他們與內部人士的對齊程度。如果內部人士在公司中持有大量股份,我認爲這是一個好跡象。內部人士擁有齊默巴奧米特控股0.1%的股份,價值約爲2800萬美元。雖然這不是一個特別高的內部持股水平,但足以表明管理層與較小股東之間存在一定的對齊。

What Might The Insider Transactions At Zimmer Biomet Holdings Tell Us?

齊默巴奧米特控股的內部交易可能告訴我們什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. Our analysis of Zimmer Biomet Holdings insider transactions leaves us cautious. But we do like the fact that insiders own a fair chunk of the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 2 warning signs for Zimmer Biomet Holdings you should be aware of.

在過去三個月中沒有發生過任何內部交易——這並不意味着太多。我們對齊默巴奧米特控股內部交易的分析讓我們保持謹慎。但我們確實喜歡內部人士擁有公司相當一部分股份。雖然關注內部人士的持股和交易情況是好的,但在做任何投資決定前,我們也會考慮面臨的風險。舉例來說:我們發現齊默巴奧米特控股有2個需要你關注的警示信號。

But note: Zimmer Biomet Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:齊默巴奧米特控股可能不是最佳的買入股票。因此,您可以查看這份有趣公司的免費名單,這些公司具有高ROE和低債務。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論